Recent price movements and market activity surrounding Ocugen stock are driven by routine small-cap biotech trading dynamics, periodic volume surges, and investor reactions to clinical pipeline updates. As a clinical-stage enterprise advancing novel gene therapies, the equity experiences sensitivity to broader healthcare sector rotations, cash burn disclosures, and upcoming regulatory trial milestones. Market participants closely monitor corporate press releases and quarterly financial disclosures to gauge operational progress and upcoming catalyst timelines.